BioAtla Inc
BCAB
Company Profile
Business description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
Contact
11085 Torreyana Road
San DiegoCA92121
USAT: +1 858 558-0708
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
41
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.60 | 16.00 | -0.18% |
| CAC 40 | 8,350.60 | 16.25 | -0.19% |
| DAX 40 | 24,942.74 | 204.29 | -0.81% |
| Dow JONES (US) | 52,508.27 | 9.63 | 0.02% |
| FTSE 100 | 10,507.64 | 21.75 | -0.21% |
| HKSE | 24,681.10 | 340.37 | 1.40% |
| NASDAQ | 26,107.01 | 233.83 | 0.90% |
| Nikkei 225 | 68,751.51 | 1,008.01 | 1.49% |
| NZX 50 Index | 13,635.07 | 16.15 | -0.12% |
| S&P 500 | 7,543.59 | 28.25 | 0.38% |
| S&P/ASX 200 | 8,841.10 | 15.90 | -0.18% |
| SSE Composite Index | 3,955.58 | 11.55 | -0.29% |